In our analysis we estimated the cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland, based on data from a pilot study. We found that a national screening programme would be expensive to implement nationally and would not be deemed cost-effective by policy makers in Ireland.
